Biosergen AS Cash Flow-to-Debt Ratio
Biosergen AS cash flow-to-debt ratio. Biosergen AS (BIOSGN) has a Cash Flow-to-Debt Ratio of -0.59x as of December 2025, meaning its operating cash flow of Skr-7.75 Million could theoretically repay -1% of its total liabilities (Skr13.04 Million) in one year. See financial agility of Biosergen AS to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Biosergen AS (2019–2025)
Cash flow-to-debt ratio of Biosergen AS from 2019 to 2025. Historical debt coverage capacity for Biosergen AS across 7 annual periods. Check Biosergen AS cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Biosergen AS Cash Flow-to-Debt Ratio by Year (2019–2025)
Biosergen AS cash flow-to-debt ratio by year from 2019 to 2025. Year-by-year debt coverage analysis for Biosergen AS. For the full cash flow conversion analysis, see BIOSGN cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (SEK) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -2.73x | Skr-35.53 Million | Skr13.04 Million | ▲ +39.2% |
| 2024 | -4.48x | Skr-16.63 Million | Skr3.71 Million | ▲ +30.1% |
| 2023 | -6.41x | Skr-32.60 Million | Skr5.08 Million | ▼ -139.5% |
| 2022 | -2.68x | Skr-29.44 Million | Skr11.00 Million | ▲ +34.4% |
| 2021 | -4.08x | Skr-37.75 Million | Skr9.25 Million | ▼ -1299.1% |
| 2020 | -0.29x | Skr-4.58 Million | Skr15.72 Million | ▼ -43.2% |
| 2019 | -0.20x | Skr-2.31 Million | Skr11.37 Million | — |